|
Jan. 19, 2026 |
|
|
April. 06, 2026 |
|
|
jRCT2031250655 |
A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Dose of MK-8507 and Multiple Once Weekly Dose of Islatravir/MK-8507 |
|
A Clinical Study of Islatravir/MK-8507 (MK-8591B) in Healthy Japanese Participants |
Yoshitsugu Hiroyuki |
||
MSD K.K. |
||
KITANOMARU SQUARE,1-13-12,Kudan-kita,Chiyoda-ku,Tokyo 102-8667,Japan |
||
+81-3-6272-1957 |
||
msdjrct@msd.com |
||
MSDJRCT inquiry mailbox |
||
MSD K.K. |
||
KITANOMARU SQUARE,1-13-12,Kudan-kita,Chiyoda-ku,Tokyo 102-8667,Japan |
||
+81-3-6272-1957 |
||
msdjrct@msd.com |
Recruiting |
Mar. 26, 2026 |
||
| April. 03, 2026 | ||
| 24 | ||
Interventional |
||
randomized controlled trial |
||
double blind |
||
placebo control |
||
parallel assignment |
||
treatment purpose |
||
Healthy male and female participants between the ages of 18 and 55 years |
||
Has a history of clinically significant abnormalities or diseases |
||
| 18age old over | ||
| 55age old under | ||
Both |
||
HIV infection |
||
Single dose of MK-8507 100, 200 and 400 mg or placebo |
||
Safety (Adverse events, discontinuation of study intervention due to adverse events), Pharmacokinetics |
||
| MSD K.K. |
| Houeikai Institutional Review Board | |
| 3-28-3, Ikebukuro, Toshima-ku, Tokyo | |
+81-3-5396-4530 |
|
| Approval | |
Feb. 12, 2026 |
Yes |
|
https://engagezone.msd.com/ |
none |